Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lemborexant

FDA-approved product (tablet, oral), marketed as Dayvigo.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Lemborexant
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Insomnia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Orexin receptor antagonists
FDA pharmacologic class
Orexin Receptor Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA58.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lemborexant in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lemborexant with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)

    NCT02783729 · start 2016-05-31

    Registered record
    Registry ID
    NCT02783729
    Conditions
    Insomnia
    Interventions
    Lemborexant; Lemborexant; Lemborexant-matched placebo; Zolpidem tartrate; Zolpidem-matched placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-05-31
    Completion
    2018-01-30
    Enrolment
    1,006

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia
    InterventionLemborexant; Lemborexant; Lemborexant-matched placebo; Zolpidem tartrate +1 more
    PhasePhase 3
    Registry statusCompleted

  • Study to Evaluate the Effect of Lemborexant Versus Placebo on Driving Performance in Healthy Adult and Elderly Subjects

    NCT02583451 · start 2015-11

    Registered record
    Registry ID
    NCT02583451
    Conditions
    Healthy Participants
    Interventions
    Placebo tablet matching lemborexant; Placebo tablet matching zopiclone; Zopiclone 7.5 mg; Lemborexant 2.5 mg; Lemborexant 5 mg; Lemborexant 10 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-11
    Completion
    2017-02
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionPlacebo tablet matching lemborexant; Placebo tablet matching zopiclone; Zopiclone 7.5 mg; Lemborexant 2.5 mg +2 more
    PhasePhase 1
    Registry statusCompleted

  • Study to Evaluate the Effect of 2 Dosage Strengths of Lemborexant (E2006) on a Multiple Sleep Latency Test in Participants With Insomnia Disorder

    NCT02350309 · start 2014-12-13

    Registered record
    Registry ID
    NCT02350309
    Conditions
    Insomnia Disorder
    Interventions
    Lemborexant 5 mg; Lemborexant 10 mg; Lemborexant-matched placebo.; Flurazepam 30 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-12-13
    Completion
    2015-04-21
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia Disorder
    InterventionLemborexant 5 mg; Lemborexant 10 mg; Lemborexant-matched placebo.; Flurazepam 30 mg
    PhasePhase 1
    Registry statusCompleted

  • A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006

    NCT01463098 · start 2011-10-05

    Registered record
    Registry ID
    NCT01463098
    Conditions
    Insomnia
    Interventions
    E2006 1.0 mg; E2006 2.5 mg; E2006 5.0 mg; E2006 10.0 mg; E2006 25.0 mg; E2006 50.0 mg; E2006 100 mg; E2006 200 mg; Zolpidem 10 mg; E2006 Matched Placebo or Zolpidem Matched Placebo; E2006 Matched Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-10-05
    Completion
    2012-08-11
    Enrolment
    122

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia
    InterventionE2006 1.0 mg; E2006 2.5 mg; E2006 5.0 mg; E2006 10.0 mg +7 more
    PhasePhase 1
    Registry statusCompleted

  • National Pregnancy Registry for Psychiatric Medications

    NCT01246765 · start 2008-11

    Registered record
    Registry ID
    NCT01246765
    Conditions
    Pregnant Women; Psychotropic Drugs
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2008-11
    Completion
    2033-12
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPregnant Women; Psychotropic Drugs
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting